Daratumumab for the treatment of multiple myeloma.

Goldsmith, S R; Foley, N; Schroeder, M A

Goldsmith, S R; Foley, N; Schroeder, M A.

Affiliation

Goldsmith SR; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Foley N; The Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, California, USA. sgoldsmith@coh.org.
Schroeder MA; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

Drugs Today (Barc) ; 57(10): 591-605, 2021 Oct.

Article in En | MEDLINE | ID: mdl-34713868

Subject(s)

Antineoplastic Agents, Immunological; Multiple Myeloma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Multiple Myeloma/drug therapy

Key words

Anti-CD38 agents; Cancer immunotherapy; Daratumumab; Hematologic malignancies; Monoclonal antibodies; Multiple myeloma

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Agents, Immunological / Multiple Myeloma Limits: Humans Language: En Journal: Drugs Today (Barc) Journal subject: MEDICINA OCUPACIONAL / SAUDE AMBIENTAL Year: 2021 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google